More bad news for Novartis on heart failure candidate PMLiVE Prospects for Novartis' acute heart failure (AHF) drug serelaxin look increasingly dim after FDA reviewers recommended against approval ahead of an advisory committee meeting tomorrow. The reviewers recommend (PDF) that the drug "not be approved at ... |
